Vaxart, Inc. – Media Coverage

Search

Year

June 08, 2022

Vaxart Announces Adjournment of Annual Meeting of Stockholders

Meeting adjourned to July 6, 2022 at 9:30 a.m. PT Vaxart encourages all stockholders of record on April 11, 2022 who have not yet voted to do so by 11:59 p.m. Eastern Time on July 5, 2022 SOUTH SAN FRANCISCO, Calif. , June 08, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc.

PDF Version

June 03, 2022

New Preclinical Data Demonstrate Two of Vaxart’s COVID-19 Vaccine Candidates Protect Against Omicron

Results provide additional support for the cross-reactivity of Vaxart’s oral vaccine candidates SOUTH SAN FRANCISCO, Calif. , June 03, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today reported positive preliminary preclinical data demonstrating that two COVID-19 vaccine candidates

PDF Version

June 02, 2022

Vaxart Reports Positive Preliminary Data from the Phase 1b Trial of its Oral Norovirus Vaccine Candidates in Elderly Adults

Results support safety and immunogenicity of the vaccine candidate in the highly vulnerable elderly population Preliminary boost study data also reported Norovirus has been estimated to cost the United States $10.6 billion annually SOUTH SAN FRANCISCO, Calif.

PDF Version

June 02, 2022

Vaxart to Participate at the Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif. , June 02, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Andrei Floroiu , President and Chief Executive Officer, Dr. Sean Tucker , SVP and Chief Scientific Officer, and Dr. James Cummings , Chief Medical Officer, will participate in a fireside

PDF Version

May 19, 2022

Vaxart Announces the Publication of Studies in the Peer-Reviewed Journal Science Translational Medicine That Suggest Mucosal Immunization Could Decrease SARS-CoV-2 Transmission

A preclinical study in hamsters showed both a decrease in infectious virus and in transmission Phase 1 data measuring cross-reactivity also included in the publication SOUTH SAN FRANCISCO, Calif. , May 19, 2022 (GLOBE NEWSWIRE) -- Science Translational Medicine has published the results of a Duke

PDF Version

May 09, 2022

Vaxart Provides Business Update and Reports First Quarter 2022 Financial Results

Data from COVID-19 Phase II study and norovirus Phase IB study are expected in 2022 Ended the 1 st Quarter with $157.0 million in cash, cash equivalents and marketable securities SOUTH SAN FRANCISCO, Calif. , May 09, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc.

PDF Version

April 14, 2022

Vaxart to Present at World Vaccine Congress Washington 2022 on April 20

SOUTH SAN FRANCISCO, Calif. , April 14, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker , SVP and Chief Scientific Officer, will present at the World Vaccine Congress Washington 2022 in Washington, D.C. on Wednesday, April 20, 2022 at 3:55 p.m. ET .

PDF Version

February 24, 2022

Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

Company begins 2022 with multiple active programs with data readouts expected this year Initial data from COVID-19 Phase II study expected in the first half of 2022 and data from several norovirus studies also expected this year Ended 2021 with $182.7 million in cash, cash equivalents and

PDF Version

February 24, 2022

Vaxart’s S-Only COVID-19 Vaccine Candidate Produces Strong-Cross Reactive Mucosal and Systemic Immune Responses in Non-Human Primates

Newly published data demonstrates substantial cross-reactivity against multiple variants of COVID-19 S-only candidate is believed to be the first to demonstrate robust neutralizing antibody responses in mucosal sites, which is where primary infection occurs Vaxart’s S-only candidate induced a

PDF Version

February 14, 2022

Vaxart Appoints Edward Berg as Senior Vice President and General Counsel

Pharmaceutical Industry Veteran Brings Broad Legal Expertise to Vaxart Senior Management Team SOUTH SAN FRANCISCO, Calif. , Feb. 14, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced the appointment of Edward B. Berg as the Company's first in-house General Counsel, effective

PDF Version

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Next page
Last page

Displaying 11 - 20 of 21

Media Coverage.

Search